S&P/ASX All Ords Index (ASX: XAO) shares have roared 20.8% higher over the past 12 months.
That's pretty impressive, but as always, there are outliers booking gains far beyond the market average.
In fact, it may surprise some ASX investors to learn that 11 All Ords shares have delivered share price growth in excess of global rock star stock Nvidia Corp (NASDAQ: NVDA) this past year.
The US chip maker has certainly dazzled us with its extraordinary near-2,400% share price growth over the past five years. And in the past 12 months, this US tech juggernaut has simply kept going.
Nvidia shares have ripped another 181% higher over 12 months to close at US$135.34 overnight. Here are the 11 homegrown businesses that have done even better than that over the period.
ASX All Ords shares beating Nvidia on price gains
Over the past year, 11 ASX All Ords shares have recorded faster share price growth than Nvidia.
Let's check them out.
1. Zip Co Ltd (ASX: ZIP)
ASX All Ords financial share Zip has gone full throttle over the past 12 months, rising 787% to $3.37 at market close on Thursday.
The buy now, pay later company has inspired new confidence from investors over the past few years after abandoning plans for global expansion to instead focus on a few core markets and achieving profitability.
2. Clarity Pharmaceuticals Ltd (ASX: CU6)
This ASX All Ords biotech share is also having a stupendous year in terms of share price growth.
The Clarity Pharmaceuticals share price has lifted by 390% over the past 12 months to $6.35.
Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company focused on developing novel cancer treatments.
Trial results on its prostate cancer treatment, 67Cu-SAR-bisPSMA, have created much excitement this year.
3. Mesoblast Ltd (ASX: MSB)
Fellow ASX All Ords biotech share Mesoblast is rising on hopes that its lead drug candidate, remestemcel-L, will finally be approved by the United States Food and Drug Administration (FDA) in January.
Branded Ryoncil, the medicine treats steroid-refractory acute graft versus host disease (SR-aGvHD) in children. The FDA has previously rejected the drug and requested more trial data from the company. Mesoblast resubmitted Ryoncil for approval in July.
The Mesoblast share price is up 343% over the past year to $1.75.
4. Sigma Healthcare Ltd (ASX: SIG)
Another ASX All Ords healthcare share has also been shooting the lights out over the past 12 months.
Sigma Healthcare's share price has surged since the company announced plans to merge with Chemist Warehouse, a privately owned national discount pharmaceutical chain. The Australian Competition & Consumer Commission (ACCC) recently green-lighted the deal.
Sigma shares are up 300% over the past year to $2.78 on Thursday.
5. Nuix Limited (ASX: NXL)
ASX All Ords tech share Nuix is also having a ripper year. The Nuix share price is up 280% over the past 12 months to $6.54 on Thursday.
Nuix provides specialised software for analysing large data sets. Blackwattle Investment Partners reckons Nuix is "arguably the best exposure to the AI thematic on the ASX".
In its full-year FY24 results, Nuix revealed a 38.7% lift in underlying earnings before interest, tax, depreciation and amortisation (EBITDA) to $64.4 million.
The other ASX All Ords shares growing faster than Nvidia stock
To recap, Nvidia shares have risen by 181% over the past 12 months.
